Tag results:

tumor-infiltrating lymphocytes

Methylation Statuses of NCOR2, PARK2, and ZSCAN12 Signify Densities of Tumor-Infiltrating Lymphocytes in Gastric Carcinoma

[Scientific Reports] Scientists developed DNA methylation markers that recapitulated the densities of tumor-infiltrating lymphocytes in gastric carcinoma.

B Cells Imprint Adoptively Transferred CD8+ T Cells with Enhanced Tumor Immunity

[Journal For Immunotherapy of Cancer] Researchers investigated how tumor-specific murine CD8+ T cells and human tumor infiltrating lymphocytes were impacted when expanded ex vivo with the TLR9 agonist CpG.

A Tumor-Specific Pro-IL-12 Activates Preexisting Cytotoxic T Cells to Control Established Tumors

[Science Immunology] Researchers developed a tumor-conditional interleukin-12 (pro-IL-12), which masked IL-12 with selective extracellular receptor–binding domains of the IL-12 receptor while preferentially and persistently activating tumor-infiltrating lymphocytes after being unmasked by matrix metalloproteinases expressed by tumors.

The Involvement of Oncobiosis and Bacterial Metabolite Signaling in Metastasis Formation in Breast Cancer

[Cancer and Metastasis Reviews] Oncobiosis in breast cancer supports invasion, metastasis, and recurrence by supporting cellular movement, epithelial-to-mesenchymal transition, cancer stem cell function, and diapedesis. The microbiome provides novel leverage on breast cancer that should be exploited for better management of the disease.

Genetic Ablation of PRDM1 in Antitumor T Cells Enhances Therapeutic Efficacy of Adoptive Immunotherapy

[Blood] Scientists identified PR domain zinc finger protein 1 (PRDM1) i.e., Blimp-1, as a key epigenetic gene associated with terminal T cell differentiation.

The Tale of TILs in Breast Cancer: A Report from the International Immuno-Oncology Biomarker Working Group

[npj Breast Cancer] The authors discuss the biological understanding of tumor-infiltrating lymphocytes (TILs), their analytical and clinical validity and efforts towards the clinical utility in breast cancer, and the current status of programmed death-ligand 1and TIL testing across different continents.

Popular